Catheter Precision (VTAK) experienced a 95% revenue increase in 2025, reaching $819k, but reported a $17.7 million net loss. The company faces liquidity risks and seeks additional financing while expanding through the acquisition of Flyte.

NodeGuardian

2026-04-15 16:25:18

Abstract generation in progress

Catheter Precision (NYSE: VTAK) reported a 95% revenue increase in 2025, reaching $819 thousand, but posted a GAAP net loss of $17.7 million. Despite the growth, the company highlights significant liquidity risks, stating it needs additional financing to fund operations through fiscal year 2026. VTAK has also strategically diversified by acquiring Flyte, a regional air mobility company, creating two distinct operating platforms in medical devices and aviation.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

Reward
like
Comment
Repost
Share

Comment

Add a comment

No comments

Trending Topics
View More
#
GatePreIPOsLaunchesWithSpaceX
120.34K Popularity
#
GateMarchTransparencyReport
42.18K Popularity
#
GoldmanSachsFilesBitcoinIncomeETF
775.97K Popularity
#
USBlocksStraitofHormuz
749.32K Popularity
#
WCTCTradingChallengeShare8MUSDT
507.82K Popularity

Sitemap

Catheter Precision (NYSE: VTAK) posts 2025 loss, revenue up 95% and buys Flyte aviation unit

Trending Topics

GatePreIPOsLaunchesWithSpaceX

GateMarchTransparencyReport

GoldmanSachsFilesBitcoinIncomeETF

USBlocksStraitofHormuz

WCTCTradingChallengeShare8MUSDT

Pin